Acutus Medical
Acutus Medical FY 2023: revenue $7.2M, down 56%; diluted EPS −$2.81
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001628280-24-014036
Key figures from this report
These are the numbers Acutus Medical reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$7.2M−56% from $16.4M in FY 202210-K income statement, on EDGAR
- Net income−$81.7MAgainst −$39.6M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$2.81Against −$1.40 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$19.2M−25% from $25.6M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$63.1MAgainst −$85.0M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- DarioHealth DRIO public float $28M, Jun 30, 2025
- Vivos Therapeutics VVOS public float $23M, Jun 30, 2025
- Nephros NEPH public float $27M, Jun 30, 2025
- Premier Air Charter Holdings PREM public float $2M, Jun 30, 2025
- Sonoma Pharmaceuticals SNOA public float $6M, Sep 30, 2025
